drugset
drugset / Trial / NCT05320809

Study of 3D189 in Patients With Hematologic Malignancies

NCT05320809 ↗

Phase 1 Active not recruiting 15 enrolled 3D Medicines
NaSingle-groupOpen-labelTreatment

Summary

To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.

Timeline

Start
2022-08-01
Primary completion
2026-06
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 3D189 Vaccine 800 ug Subcutaneous

Indications

acute leukemia myelodysplastic syndrome non-Hodgkin lymphoma plasma cell myeloma